Investigator

Diddier Prada

Assistant Professor · Icahn School of Medicine at Mount Sinai, Population Health Science and Policy

DPDiddier Prada
Papers(1)
Associations between …
Collaborators(2)
Jairo Rubio-CorderoDavid Cantú-De León
Institutions(2)
Unknown InstitutionInstituto Nacional de…

Papers

Associations between the prognostic nutritional index and response to neoadjuvant chemotherapy in patients with epithelial ovarian cancer

To evaluate the association between the prognostic nutritional index and the response to neoadjuvant chemotherapy in Mexican patients with epithelial ovarian cancer. Retrospective analyses of 220 patients with epithelial ovarian cancer treated with neoadjuvant therapy. The cutoff points for the prognostic nutritional index at diagnosis and after neoadjuvant therapy were determined via receiver operating characteristic curves. Categorical variables were analyzed with the χ The median age was 55 years (range; 28-82). The most common histology was high-grade serous carcinoma in 199 cases (90.5%), and 66.4% (n = 146) were International Federation of Gynecology and Obstetrics stage IIIC. The prognostic nutritional index cutoff points at diagnosis and after neoadjuvant chemotherapy for complete or optimal cytoreduction were 40.5 and 45, respectively. High prognostic nutritional index values were associated with higher rates of complete or optimal cytoreduction: 53.6% and 67.7%, respectively. Additionally, high prognostic nutritional index values were associated with platinum sensitivity. According to the multivariate analysis, a high prognostic nutritional index value (OR 6.6, p = .001) was an independent factor associated with complete or optimal cytoreduction. The median overall survival at 3 years was not reached in patients with high prognostic nutritional index values (p = .054 and p = .015). Disease-free survival was not significantly different for high versus low prognostic nutritional index values (p = .9). The prognostic nutritional index may be used as an independent prognostic biomarker for advanced epithelial ovarian cancer.

5Works
1Papers
2Collaborators
PrognosisStomach NeoplasmsAdenocarcinomaBiomarkers, TumorCarcinoma, Ovarian EpithelialOvarian NeoplasmsBreast NeoplasmsLeukemia, Myelogenous, Chronic, BCR-ABL Positive

Positions

2023–

Assistant Professor

Icahn School of Medicine at Mount Sinai · Population Health Science and Policy

2019–

Associate Research Scientist

Columbia University Mailman School of Public Health · Environmental Health Sciences

2014–

Research Associate

Harvard T.H. Chan School of Public Health · Environmental Health Science

Education

2012

PhD

Universidad Nacional Autónoma de México · Medicina Genomica y Toxicologia Ambiental

2001

MD

Industrial University of Santander · Facultad de Medicina

Links & IDs
0000-0002-6517-156X

Scopus: 23991301400